Yang S, Lu HS, Zhang XF, Huang CM, Wang C, Wu XY, Guan GX. Efficacy of lobaplatin plus 5-fluorouracil and leucovorin in the treatment of advanced gastric cancer: a report of 30 cases.
Shijie Huaren Xiaohua Zazhi 2010;
18:1063-1066. [DOI:
10.11569/wcjd.v18.i10.1063]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the efficacy and safety of lobaplatin (LBP) plus 5-fluorouracil (5-FU) and leucovorin (CF) in the treatment of advanced gastric cancer.
METHODS: The clinical data for 30 patients with advanced gastric cancer treated with LBP plus 5-FU and CF from March 2004 to September 2008 were retrospectively reviewed. All patients received at least two cycles of chemotherapy, each lasting 21 days and consisting of LBP 30 mg/m2 IV d 1, 5-FU 300 mg/m2 IV d 1-5, and CF 100 mg/m2 IV d 1-5.
RESULTS: Thirty patients received 2 to 6 cycles of chemotherapy, with a median of three cycles. All patients were evaluable for efficacy and toxicity. No patients obtained a complete response. Partial response was achieved in 12 patients, stable disease in 5 patients, and progressive disease in 13 patients. The objective response rate was 40% (12/30). The tumor control rate was 56.7% (17/30). Therapy was generally well tolerated. Major toxicity was myelosuppression and gastrointestinal sensitivity, including anaemia, thrombocytopenia, leukocytopenia, and nausea and vomiting. No chemotherapy-related death occurred.
CONCLUSION: LBP plus 5-FU and CF regimen is effective and safe for patients with advanced gastric cancer.
Collapse